The startup develops a personalized cancer treatment platform that utilizes cell therapy and drug discovery to deliver targeted therapies for specific cancer types. It also focuses on treating severe liver disease by reducing fibrosis in cirrhosis and promoting liver regeneration through effective and safe treatment methods.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for non-compensated liver cirrhosis are limited, with liver transplantation being the only option for many patients, but a shortage of donors restricts access. Existing therapies often fail to effectively reduce liver fibrosis or promote sufficient liver regeneration, leading to high mortality rates.
Solution
KanonCure is developing regenerative medicine products and pharmaceuticals targeting liver diseases, with a focus on non-compensated liver cirrhosis. Their primary therapeutic approach involves a cell sheet composed of liver cells derived from mesenchymal stem cells using a proprietary small molecule compound, IC-2. This cell sheet is designed to be applied to the liver surface to reduce fibrosis and promote liver regeneration. In addition, KanonCure is developing small molecule drugs targeting organ fibrosis, liver cancer, and colon cancer.
Target Audience
The primary target audience includes patients with non-compensated liver cirrhosis and liver cancer, as well as medical professionals in gastroenterology and hepatology.
Features
- Cell sheet technology utilizing IC-2 to transform mesenchymal stem cells into liver cells
- Cell sheets designed to reduce liver fibrosis by 40%, promoting liver regeneration
- Small molecule compounds targeting Wnt/β-catenin pathways for liver and colon cancer
- Three small molecule compounds with granted substance patents, with applications pending in multiple countries
- Exploring the potential of small molecule compounds for COVID-19 prevention and treatment